The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Inclusion Criteria: * Presence of signed informed consent to participate in the trial. * Volunteers (both male and female) over the age of 60 who could meet the Protocol requirements. * Negative pregnancy test obtained from female volunteers with preserved childbearing potential. * Consent to use adequate contraception methods (contraception methods with degree of reliability of more than 90%: a nonhormonal intrauterine device; a spermicide condom; a spermicide cervical cap; spermicide diaphragms) or total sexual abstinence during the clinical trial (until Visit 5 (day 28(+2)). Exclusion Criteria: * Allergic reactions to chicken protein or any previous influenza vaccination. * Anamnestic data on the episodes of severe allergic reactions and/or diseases (anaphylaxis, Quincke's edema, polymorphic exudative erythema, serum disease etc.) * Acute reaction (temperature above 38.5оС, edema and hyperemia over 5 cm in diameter at the injection site) or complications caused by previous administration of the drug. * Previous vaccination 6 months before the start of the trial. * History of leucosis, blood cancer, malignant oncological diseases. * Guillain-Barré syndrome (acute polyneuropathy) in the medical history. * Positive screening for HIV infection, B and C hepatitis, syphilis. * Any confirmed or suspected immunosuppressive or immunodeficiency condition; * Administration of immunoglobulin or blood products within the last three months before the study. * Long-term use (more than 14 days) of immunosuppressants (including systemic corticosteroids, cytotoxic, radioactive preparations) or other immunomodulatory drugs for six months before the trial. * Chronic diseases at the decompensation stage or in debilitating form, which can make it dangerous for the volunteer to take part in the trial. * Progressive neurological disorders, dementia. * Blood disorders which serve as a contradiction for intramuscular injection. * History of alcohol or drug addiction. * Pregnancy, breastfeeding in women with preserved reproductive performance. * Current participation in another clinical trial or within the previous 3 months before the screening. * Mental, physical and other problems which do not allow for appropriate assessment of own behavior and following the requirements set out in the trial protocol. * Any other conditions which in the reasonable opinion of the clinical investigator complicate the participation of the volunteer in the trial